Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.74 |
| ▸ | FECH | P22830 | 1/20 | 0.74 |
| ▸ | CDK8 | P49336 | 1/20 | 0.74 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.74 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.74 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962911 | 1.00 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL4963504 | 0.94 | ERBB2 (0.85) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL4963510 | 0.94 | ERBB2 (0.85) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6173414 | 0.92 | ERBB2 (0.86) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6173407 | 0.92 | ERBB2 (0.86) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6175088 | 0.91 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6175084 | 0.91 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6474655 | 0.87 | ERBB2 (0.84) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6173402 | 0.87 | ERBB2 (0.84) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6174379 | 0.86 | ERBB2 (0.86) | EGFRERBB2FECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254204-A1 | Bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2004-12-16 | — | — | US | claimed |
| EP-1896451-A2 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070072885-A1 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2007-03-29 | — | — | US | disclosed |
| WO-2006129168-A2 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20040254204-A1 | Bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072885-A1 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | UGT1A1, CCNA1, UGT1A3 | EGFR 320/4885ERBB2 967/4885FECH 3177/4885 |
| US-20040254204-A1 | Bicyclic derivatives for the treatment of abnormal cell growth | UGT1A1, UGT1A3, UGT2B17 | EGFR 342/4885ERBB2 966/4885FECH 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.